Starboard gauges Bristol-Myers shareholder support for Celgene deal
February 15, 2019 at 21:09 PM EST
Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.